We've appealed Nasdaq's delisting decision, citing our recent achievements in neurological disorder treatments. Key milestones include FDA briefing book submission and supplying suramin for a health crisis in Malawi. $PXMD Read more: https://ibn.fm/ubLov
PaxMedica, Inc.
Biotechnology Research
Tarrytown , NY 767 followers
Empowering Possibilities, Transforming Lives: PaxMedica's Journey in Neurodevelopmental Solutions
About us
PaxMedica (OTCQB: PXMD) is a forward-thinking clinical-stage biopharmaceutical company, unwavering in its dedication to advancing innovative therapies for individuals and families impacted by neurodevelopmental disorders. With a primary focus on Autism Spectrum Disorder (ASD), PaxMedica is committed to developing groundbreaking treatments that address the unmet medical needs of those affected by this complex condition. Our team of dedicated experts and scientists collaborates passionately to bring meaningful advancements to the field, aiming to provide relief from the core symptoms of autism and improve the overall quality of life for those affected. We believe in the power of scientific innovation, and we are committed to making a real difference for individuals with ASD and their families. Join us on our mission to bring about transformative change in the world of neurodevelopmental disorders.
- Website
-
http://www.paxmedica.com
External link for PaxMedica, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Tarrytown , NY
- Type
- Public Company
- Founded
- 2010
Locations
-
Primary
Get directions
303 S Broadway
Suite 125
Tarrytown , NY 10591, US
Employees at PaxMedica, Inc.
Updates
-
Howard Weisman, our CEO, and Dr. Marshal Lemerani from Malawi Ministry of Health discuss PaxMedica's swift response to an urgent medical crisis. Learn how we're addressing the shortage of medications for sleeping sickness below! $PXMD Listen now: https://ibn.fm/iD1Lh
-
PaxMedica, Inc. reposted this
🚨 Urgent news from PaxMedica Inc.! In response to an emergency request from Malawi's Ministry of Health, we're committing to provide immediate access to IV suramin (PAX-101) to combat the life-threatening sleeping sickness crisis in the region Read more: https://ibn.fm/0mVVT
-
-
🚨 Urgent news from PaxMedica Inc.! In response to an emergency request from Malawi's Ministry of Health, we're committing to provide immediate access to IV suramin (PAX-101) to combat the life-threatening sleeping sickness crisis in the region Read more: https://ibn.fm/0mVVT
-
-
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 https://lnkd.in/eTmgPhgV
-
🌍 Urgent humanitarian news! We've received an urgent request from Malawi's Ministry of Health for emergency access to IV suramin to combat a potential crisis. This underscores the critical need for suramin in treating trypanosomal infections and saving lives. PaxMedica is working with the FDA to address this request and advance its treatment development. #PaxMedica #Healthcare #EmergencyResponse $PXMD Read more: https://ibn.fm/qQsnX
-
-
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness https://lnkd.in/efxMBNt5
-
$PXMD Announces ‘Milestone Achievement’ on Journey to Developing PAX-101 #AutismAwareness #HealthTech https://ibn.fm/IgGLA
-
-
BioMedNewsBreaks — $PXMD Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions https://ibn.fm/IS1Tk #PaxMedica #AutismAwareness
-
-
$PXMD Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium #PaxMedica #AutismAwareness https://ibn.fm/f3s7B
-